Literature DB >> 26646957

[Cervical cancer is a clinical challenge].

Maria Bjurberg1, Catharina Beskow2, Päivi Kannisto3, Gabriel Lindahl4.   

Abstract

Cervical cancer is the third most common female cancer world wide. In Sweden, some 450 cases are diagnosed annually. One out of three affected Swedish women is under the age of 40. Survival for all stages is 73 % in Sweden. Human papilloma virus (HPV) can be detected in the majority of all cervical cancers. Treatment consists of surgery for early stages, and a combination of chemoradiation and brachytherapy for locally advanced disease. For metastatic disease, the treatment is palliative. Late side effects after treatment may have serious impact on the quality of life. There is a strong need for more efficient treatment of metastatic disease. Current lines of research include surgical strategies, optimised radiotherapy, neoadjuvant therapy, targeted therapy, and immunotherapy including therapeutic vaccines.

Entities:  

Mesh:

Year:  2015        PMID: 26646957

Source DB:  PubMed          Journal:  Lakartidningen        ISSN: 0023-7205


  2 in total

1.  Long noncoding RNA HOXC-AS3 enhances the progression of cervical cancer via activating ErbB signaling pathway.

Authors:  Runsheng Zhao; Jing Song; Yiqiang Jin; Yingying Liu
Journal:  J Mol Histol       Date:  2021-08-13       Impact factor: 2.611

2.  Identification of autophagy-related risk signatures for the prognosis, diagnosis, and targeted therapy in cervical cancer.

Authors:  Dan Meng; Hua Jin; Yun Gu; Shizhi Wang; Xing Zhang; Wenjing Yan; Qianqian Xia; Siyuan Shen; Shuqian Xie; Mengjing Cui; Bo Ding
Journal:  Cancer Cell Int       Date:  2021-07-08       Impact factor: 5.722

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.